AB209835

Anti-VEGFA antibody

Lab Essentials
What is this?

Be the first to review this product! Submit a review

(2 Publications)

Rabbit Polyclonal VEGFA antibody. Suitable for IHC - Wmt and reacts with Zebrafish samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Zebrafish vegfaa aa 1 to C-terminus.

View Alternative Names

vegf, vegfa, vegfaa, Vascular endothelial growth factor A-A, VEGF-A-A

2 Images

IHC - Wholemount - Anti-VEGFA antibody (AB209835)

IHC - Wmt

Supplier Data

IHC - Wholemount - Anti-VEGFA antibody (AB209835)

Immunohistochemical analysis of 2 days-post-fertilization zebrafish embryo labeling VEGFA with ab209835 at 1/200.

IHC - Wmt

Supplier Data

IHC - Wholemount - Anti-VEGFA antibody (AB209835)

Immunohistochemical analysis of paraformaldehyde-fixed zebrafish embryos labeling VEGFA with ab209835 at 1/200.

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

Reacts with

Zebrafish

Applications

IHC - Wmt

applications

Immunogen

Recombinant Fragment Protein within Zebrafish vegfaa aa 1 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

O73682

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCWmt" : {"fullname" : "IHC - Wholemount", "shortname":"IHC - Wmt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Zebrafish": { "IHCWmt-species-checked": "testedAndGuaranteed", "IHCWmt-species-dilution-info": "1/100 - 1/500", "IHCWmt-species-notes": "<p></p>" } } }

style

left-column

Product details

Please refer to the vial label for the specific concentration.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Immunogen

Storage buffer

pH: 7 Preservative: 0.01% Thimerosal (merthiolate) Constituents: PBS, 20% Glycerol (glycerin, glycerine)

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Vascular endothelial growth factor A (VEGFA) also known as VEGF or vascular permeability factor (VPF) is a protein that plays a central role in angiogenesis as well as in the growth of blood vessels. The molecular weight of VEGFA varies depending on the isoform typically ranging from 34 to 42 kDa. VEGFA is expressed in many tissues including fibroblasts macrophages endothelial cells and platelets. Its expression levels can increase in response to stimuli like hypoxia or inflammatory cytokines. VEGFA is an important target in research for therapies related to vascular diseases and cancer.

Biological function summary

VEGFA functions by promoting the proliferation and migration of vascular endothelial cells. It operates both as a homodimer and as part of complex signaling cascades interacting with VEGF receptors on cell surfaces to trigger downstream signals for angiogenesis. This includes endothelial cell growth migration and the new blood vessel formation process. VEGFA's activity is important for physiological processes such as wound healing and embryonic development and it also contributes to pathological conditions through its unregulated expression in diseases.

Pathways

Many processes involve VEGFA including the PI3K/AKT pathway and the MAPK/ERK pathway. These pathways regulate cell survival growth and differentiation. Other proteins like PLGF (placenta growth factor) and VEGFB often accompany VEGFA in these pathways aiding in distinct but overlapping roles. These interactions are transmitted through binding to VEGF receptors such as VEGFR-1 and VEGFR-2 subsequently activating various signaling cascades necessary for cellular and tissue homeostasis.

VEGFA relates to cancer and age-related macular degeneration among others. In cancer overexpression of VEGFA can lead to excessive angiogenesis supplying blood to tumors and facilitating tumor growth. In age-related macular degeneration upregulation of VEGFA contributes to the progression of the disease by promoting the formation of abnormal blood vessels under the retina. Anti-VEGFA therapies such as anti-VEGF antibodies (e.g. bevacizumab) can target these overexpressed pathways. VEGFA interacts with other proteins like HIF-1α which regulates its expression under hypoxia a common condition in tumors.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis, and induces permeabilization of blood vessels. Required for intersegmental vessel development in the tail during embryogenesis (PubMed : 15305301). Acts both upstream of kdr and tie1 to stimulate endothelial cell differentiation, and upstream of gata1 to stimulate hematopoietic cell differentiation.

See full target information vegfaa

style

left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Comparative biochemistry and physiology. Part A, Molecular & integrative physiology 275:111340 PubMed36347467

2022

Cardiovascular oxygen transport and peripheral oxygen extraction capacity contribute to acute heat tolerance in European seabass.

Applications

Unspecified application

Species

Unspecified reactive species

Katja Anttila,Florian Mauduit,Mirella Kanerva,Miriam Götting,Mikko Nikinmaa,Guy Claireaux

Frontiers in oncology 10:162 PubMed32133296

2020

Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry.

Applications

Unspecified application

Species

Unspecified reactive species

Hanna Engqvist,Toshima Z Parris,Anikó Kovács,Elisabeth Werner Rönnerman,Karin Sundfeldt,Per Karlsson,Khalil Helou

View all publications

style

left-column

style

left-column

style

right-column